ArticleFrontiers in immunology2026
Microfluidic dissociation of spleen to recover immune cells for biotechnology and single cell analysis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Introduction: Splenocytes are important for various applications in medicine and biotechnology, but isolation methods are often limited by low yield, poor viability, bias towards certain cell subtypes, and degradation of surface marker expression. Here, we employ a microfluidic device to dissociate spleen tissue and isolate single splenocytes using non-enzymatic, enzymatic, and combined approaches. Methods: Spleen samples were minced and digested on-chip using enzyme-free buffer to assess short-term release of predominantly non-adherent CD45+ leukocyte populations. We then evaluated isolation of dendritic cells and macrophages by comparing non-enzymatic and enzymatic digestion protocols over time. A combined protocol, consisting of a buffer washout followed by collagenase digestion, was then used to balance enzyme exposure and maximize recovery. Results: Microfluidic digestion yielded greater cell recovery and viability across non-adherent splenocytes (B cells and T cell subpopulations) and adherent splenocytes (dendritic cells, macrophages, and neutrophils) within the CD45+ leukocyte population, compared to conventional strainer grinding and collagenase digestion controls. Functional validation was performed for B cells, which were isolated using the final protocol and cultured for six days, demonstrating comparable proliferation, viability, and antibody production levels relative to controls. Discussion: Future studies will evaluate additional splenocyte subpopulations using functional assays and downstream applications in medicine and biotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.